Pharmasset, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 71   

Articles published

VRUS 0.0000
price chart
Gilead bets $11 billion on hepatitis in Pharmasset deal
(Reuters) - Gilead Sciences Inc (GILD.O) struck a deal to buy biotechnology company Pharmasset Inc VRUS.O for about $11 billion in a huge and risky bet on the next generation of hepatitis C treatments.
Gilead Sciences to Acquire Pharmasset, Inc. for $11 Billion  Business Wire (press release)
Gilead to Acquire Pharmasset for $11 Billion to Add Hepatitis C Medicines  Bloomberg
Related articles »  
Pharmasset Inc. (VRUS) President and CEO P Schaefer Price sells 20000 Shares
President and CEO of Pharmasset Inc. (VRUS) P Schaefer Price sells 20,000 shares of VRUS on 08/01/2011 at an average price of $120.15 a share.
Pharmasset Inc. Reports Operating Results (10-K)
Pharmasset Inc. has a market cap of $5.2 billion; its shares were traded at around $68.93 with and P/S ratio of 5095.7. Highlight of Business Operations: At least six major genotypes of HCV have been identified, each with multiple subtypes.
Pharmasset Reports Fiscal Year End 2011 Financial Results  PR Newswire (press release)
Related articles »  
Costs of New Treatments for Hepatitis C Infection
The authors' use of Pharmasset's sales price as a proxy for the cost of developing sofosbuvir greatly overestimates the true development costs.
Related articles »  
Losing to win, in pro basketball and business
In business, just like sports, we are taught to win. Gain profits today. Get larger now. Beat the competition every time. That's why it's so rare to see a sports team so obviously try to not win a championship, or even get to the playoffs.
Sovaldi patent case hits the UK courts � decision expected Q4 2014
Sofosbuvir was initially developed in the labs of an American company called Pharmasset. Pharmasset was bought by Gilead Sciences Inc. in 2012 for $11.1bn, despite a rather complex patent landscape and contractual claims over the rights to the ...
Alzheon Appoints Renowned Industry Leader, Jean-Pierre Sommadossi, PhD, to ...
Dr. Sommadossi is the principal founder of Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) and a co-founder of Pharmasset, Inc. Both of these companies were acquired; Idenix by Merck for $3.85 billion in 2014, and Pharmasset by Gilead for $11.1 billion in ...
Related articles »  
Neustatter: Prescription pill prices can be eye-popping
Many of you have filled a prescription for some relatively mundane drug - and needed another prescription for a tranquilizer. Consider yourself lucky you are not having to fill a prescription for the new hepatitis C drug Sovaldi, which costs $1,000 a ...
Tekmira teams up with OnCore to focus on hepatitis B cure
OnCore was founded in 2012 by former Pharmasset Inc. executives after Gilead bought Pharmasset. U.S.-traded shares of Tekmira Pharmaceuticals Corp.
Tekmira Pharmaceuticals and OnCore Biopharma Announce Merger Agreement ...  GlobeNewswire (press release)
Carl Icahn stands to lose US$286 million on Talisman Energy Inc deal
Icahn, 78, in recent years has invested in U.S. companies including Herbalife Ltd., EBay Inc. and Apple Inc. His net worth has dropped by about US$778 million this year, according to the Bloomberg Billionaires Index, to US$22 billion.
Related articles »